Literature DB >> 22699518

Sensitivity of MDM2 amplification and unexpected multiple faint alphoid 12 (alpha 12 satellite sequences) signals in atypical lipomatous tumor.

Takeshi Kashima1, Dina Halai, Hongtao Ye, Sandra Nalini Hing, David Delaney, Robin Pollock, Paul O'Donnell, Roberto Tirabosco, Adrienne Margaret Flanagan.   

Abstract

This study assessed whether analysis of MDM2 copy number by fluorescence in situ hybridization (FISH) would help distinguish lipomas from atypical lipomatous tumors, otherwise referred to as well-differentiated liposarcomas, using a commercially available MDM2 FISH kit. 227 lipomatous and 201 non-lipomatous tumors were analyzed to assess its sensitivity and specificity. Of 178 mature lipomatous tumors, 86 were classified histologically as lipoma and 92 as atypical lipomatous tumor. Two of the lipomas harboring MDM2 amplification were reclassified as atypical lipomatous tumors. Overall, 13 atypical lipomatous tumors did not reveal MDM2 or CDK4 amplification, although this was reduced to 12 following analysis of multiple slides. Three of these cases revealed very occasional tumor cells harboring high-level MDM2 amplification, two had a dedifferentiated component, and MDM2 amplification was detected when one tumor recurred. The remaining six cases exhibited reactive/inflammatory features and were reclassified as lipomas. The findings indicate that MDM2 amplification is 93.5% sensitive for diagnosing atypical lipomatous tumor. A total of 2 of the 20 dedifferentiated liposarcomas failed to reveal MDM2 amplification. All atypical lipomatous tumors measured >10 cm, two dedifferentiated liposarcoma presented de novo at <10 cm, and ~50% of lipomas measured >10 cm. Spindle cell lipomas, lipoblastomas, hibernomas and pleomorphic liposarcomas did not reveal MDM2 amplification. Of 201 non-lipomatous tumors, eight revealed MDM2 amplification or multiple faint alphoid 12 signals and were reclassified as dedifferentiated liposarcoma. Multiple faint alphoid 12 signals were observed in nine tumors from seven patients, an observation not previously reported on paraffin sections: these included four atypical lipomatous tumors, and three dedifferentiated liposarcomas, one previously diagnosed as a myxofibrosarcoma, all of which also revealed amplification of CDK4, although two lacked MDM2 amplification. MDM2 FISH test is a useful adjunct to histology for distinguishing lipoma from atypical lipomatous tumor. The limitations of molecular genetic tests must be known before introducing them into a clinical service.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22699518     DOI: 10.1038/modpathol.2012.90

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  20 in total

1.  Locally aggressive fibrous dysplasia.

Authors:  T G Kashima; N M Gamage; H Ye; M F Amary; A M Flanagan; S J Ostlere; N A Athanasou
Journal:  Virchows Arch       Date:  2013-06-13       Impact factor: 4.064

Review 2.  Recent translational research into targeted therapy for liposarcoma.

Authors:  Rashi Bharat Patel; Ting Li; Zhichao Liao; Jivani Aakash Jaldeepbhai; H A Pavanika N V Perera; Sujani Kaushalya Muthukuda; Dholiya Hardeep Dhirubhai; Vaibhav Singh; Xiaoling Du; Jilong Yang
Journal:  Stem Cell Investig       Date:  2017-03-15

3.  Dermpath quiz.

Authors:  Viktoryia Kazlouskaya; Elen Blochin; Karan Lal; Paul M Parker; Dirk M Elston
Journal:  Indian Dermatol Online J       Date:  2013-10

4.  The General Surgeon's quandary: atypical lipomatous tumor vs lipoma, who needs a surgical oncologist?

Authors:  Sarah B Fisher; Katherine J Baxter; Charles A Staley; Kevin E Fisher; David K Monson; Douglas R Murray; Shervin V Oskouei; Sharon W Weiss; David A Kooby; Shishir K Maithel; Keith A Delman
Journal:  J Am Coll Surg       Date:  2013-09-25       Impact factor: 6.113

5.  MRI characteristics of lipoma and atypical lipomatous tumor/well-differentiated liposarcoma: retrospective comparison with histology and MDM2 gene amplification.

Authors:  Mélanie Brisson; Takeshi Kashima; David Delaney; Roberto Tirabosco; Andrew Clarke; Suzie Cro; Adrienne M Flanagan; Paul O'Donnell
Journal:  Skeletal Radiol       Date:  2012-09-18       Impact factor: 2.199

6.  Qualitative evaluation of MRI features of lipoma and atypical lipomatous tumor: results from a multicenter study.

Authors:  Lorenzo Nardo; Yasser G Abdelhafez; Francesco Acquafredda; Silvia Schirò; Andrew L Wong; Dani Sarohia; Roberto Maroldi; Morgan A Darrow; Michele Guindani; Sonia Lee; Michelle Zhang; Ahmed W Moawad; Khaled M Elsayes; Ramsey D Badawi; Thomas M Link
Journal:  Skeletal Radiol       Date:  2020-01-22       Impact factor: 2.199

7.  GNAS mutations are not detected in parosteal and low-grade central osteosarcomas.

Authors:  Carolina Salinas-Souza; Carlos De Andrea; Michel Bihl; Michal Kovac; Nischalan Pillay; Tim Forshew; Alice Gutteridge; Hongtao Ye; M Fernanda Amary; Roberto Tirabosco; Silvia Regina Caminada Toledo; Daniel Baumhoer; Adrienne M Flanagan
Journal:  Mod Pathol       Date:  2015-08-07       Impact factor: 7.842

8.  Fluorescence In Situ Hybridization for MDM2 Amplification as a Routine Ancillary Diagnostic Tool for Suspected Well-Differentiated and Dedifferentiated Liposarcomas: Experience at a Tertiary Center.

Authors:  Khin Thway; Jayson Wang; John Swansbury; Toon Min; Cyril Fisher
Journal:  Sarcoma       Date:  2015-02-25

9.  Challenging dedifferentiated liposarcoma identified by MDM2-amplification, a report of two cases.

Authors:  Suvi Lokka; Andreas H Scheel; Sebastian Dango; Katja Schmitz; Rudolf Hesterberg; Josef Rüschoff; Hans-Ulrich Schildhaus
Journal:  BMC Clin Pathol       Date:  2014-07-28

10.  Clinical outcome in patients with peripherally-sited atypical lipomatous tumours and dedifferentiated liposarcoma.

Authors:  Sangeetha N Kalimuthu; Charles Tilley; Georgina Forbes; Hongtao Ye; Katie Lehovsky; Nischalan Pillay; Beatrice M Seddon; Paul O'Donnell; Robin Pollock; Roberto Tirabosco; M Fernanda Amary; Adrienne M Flanagan
Journal:  J Pathol Clin Res       Date:  2015-03-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.